ArticleNeurology and therapy2023

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells.

Radu Tanasescu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.